SB SCIENCE MANAGEMENT UG

Their core work

SB Science Management is a Berlin-based SME specializing in science management and project support services for EU-funded research consortia. Their involvement as a third party in two projects and participant in one suggests they provide administrative, coordination, or dissemination services rather than core laboratory research. Their projects span diverse scientific domains — from chromatin biology and systems medicine to industrial biotechnology — which is consistent with a management-oriented role that adapts to different research contexts. Their most recent project (OXIPRO) positions them closer to industry-driven consumer product innovation involving enzyme technology.

What they specialise in

How they've shifted over time

Their earliest involvement (Chromatin3D, 2015) was in fundamental life sciences research with no detailed keyword trail. By 2018, they moved into applied systems medicine with PoLiMeR, working on computational modeling of liver metabolism and iPSC-based disease models. Their most recent project (OXIPRO, 2021) marks a clear pivot toward industry-driven biotechnology — enzyme applications for consumer goods with a sustainability and circularity agenda. The trajectory shows a shift from basic biomedical research support toward applied, market-oriented science management.

Moving toward industry-driven, sustainability-focused projects where science management bridges the gap between enzyme research and consumer product markets.

How they like to work

SB Science Management has never coordinated a project — they join as a third party or participant, which is typical for service-oriented SMEs that provide management or dissemination support to larger research consortia. With 49 unique partners across 18 countries from just three projects, they operate within large, internationally diverse consortia rather than small focused teams. This breadth of network exposure, combined with their support-oriented role, makes them a low-risk addition to consortia needing project management capacity.

Despite only three projects, they have built connections with 49 unique partners across 18 countries, reflecting their participation in large MSCA training networks and RIA consortia. Their network is pan-European with no obvious geographic concentration.

What sets them apart

Their value lies in being a flexible science management partner that can operate across very different research domains — from chromatin biology to enzyme-based consumer products. For consortium builders, they offer a Berlin-based SME that satisfies SME participation requirements while contributing project management expertise rather than competing for research tasks. Their recent move into RRI and consumer-oriented co-creation for OXIPRO suggests growing capability in public engagement and responsible innovation activities.

Highlights from their portfolio

• OXIPRO
  Their only project with direct EC funding (€282K), and a shift into applied industrial biotechnology targeting consumer products through oxidoreductase enzymes and circular economy principles.
• PoLiMeR
  A five-year MSCA training network on liver disease modeling combining computational approaches (genome-scale models) with advanced experimental platforms (organ-on-chip, iPSC).